Isotretinoin REMS Modifications Show How Advisory Panel Can Push FDA To Change Its Mind

US FDA makes five changes to ease burden of risk management program for acne drug – going further than the agency initially seemed comfortable with in March, though not always in line with what the generic sponsors were seeking.